665 related articles for article (PubMed ID: 24502949)
1. Blocking the NOTCH pathway can inhibit the growth of CD133-positive A549 cells and sensitize to chemotherapy.
Liu J; Mao Z; Huang J; Xie S; Liu T; Mao Z
Biochem Biophys Res Commun; 2014 Feb; 444(4):670-5. PubMed ID: 24502949
[TBL] [Abstract][Full Text] [Related]
2. Cisplatin selects for multidrug-resistant CD133+ cells in lung adenocarcinoma by activating Notch signaling.
Liu YP; Yang CJ; Huang MS; Yeh CT; Wu AT; Lee YC; Lai TC; Lee CH; Hsiao YW; Lu J; Shen CN; Lu PJ; Hsiao M
Cancer Res; 2013 Jan; 73(1):406-16. PubMed ID: 23135908
[TBL] [Abstract][Full Text] [Related]
3. NOTCH pathway blockade depletes CD133-positive glioblastoma cells and inhibits growth of tumor neurospheres and xenografts.
Fan X; Khaki L; Zhu TS; Soules ME; Talsma CE; Gul N; Koh C; Zhang J; Li YM; Maciaczyk J; Nikkhah G; Dimeco F; Piccirillo S; Vescovi AL; Eberhart CG
Stem Cells; 2010 Jan; 28(1):5-16. PubMed ID: 19904829
[TBL] [Abstract][Full Text] [Related]
4. Gamma-Secretase Inhibitor IX (GSI) Impairs Concomitant Activation of Notch and Wnt-Beta-Catenin Pathways in CD44
Barat S; Chen X; Cuong Bui K; Bozko P; Götze J; Christgen M; Krech T; Malek NP; Plentz RR
Stem Cells Transl Med; 2017 Mar; 6(3):819-829. PubMed ID: 28186678
[TBL] [Abstract][Full Text] [Related]
5. Combination Treatment with All-Trans Retinoic Acid Prevents Cisplatin-Induced Enrichment of CD133+ Tumor-Initiating Cells and Reveals Heterogeneity of Cancer Stem Cell Compartment in Lung Cancer.
Moro M; Bertolini G; Pastorino U; Roz L; Sozzi G
J Thorac Oncol; 2015 Jul; 10(7):1027-36. PubMed ID: 26020124
[TBL] [Abstract][Full Text] [Related]
6. HtrA1 downregulation induces cisplatin resistance in lung adenocarcinoma by promoting cancer stem cell-like properties.
Xu Y; Jiang Z; Zhang Z; Sun N; Zhang M; Xie J; Li T; Hou Y; Wu D
J Cell Biochem; 2014 Jun; 115(6):1112-21. PubMed ID: 24356998
[TBL] [Abstract][Full Text] [Related]
7. Cucurbitacin I inhibits tumorigenic ability and enhances radiochemosensitivity in nonsmall cell lung cancer-derived CD133-positive cells.
Hsu HS; Huang PI; Chang YL; Tzao C; Chen YW; Shih HC; Hung SC; Chen YC; Tseng LM; Chiou SH
Cancer; 2011 Jul; 117(13):2970-85. PubMed ID: 21225866
[TBL] [Abstract][Full Text] [Related]
8. Notch pathway inhibition using DAPT, a γ-secretase inhibitor (GSI), enhances the antitumor effect of cisplatin in resistant osteosarcoma.
Dai G; Deng S; Guo W; Yu L; Yang J; Zhou S; Gao T
Mol Carcinog; 2019 Jan; 58(1):3-18. PubMed ID: 29964327
[TBL] [Abstract][Full Text] [Related]
9. Gamma-secretase inhibitor prevents Notch3 activation and reduces proliferation in human lung cancers.
Konishi J; Kawaguchi KS; Vo H; Haruki N; Gonzalez A; Carbone DP; Dang TP
Cancer Res; 2007 Sep; 67(17):8051-7. PubMed ID: 17804716
[TBL] [Abstract][Full Text] [Related]
10. Colorectal cancer stem cell and chemoresistant colorectal cancer cell phenotypes and increased sensitivity to Notch pathway inhibitor.
Huang R; Wang G; Song Y; Tang Q; You Q; Liu Z; Chen Y; Zhang Q; Li J; Muhammand S; Wang X
Mol Med Rep; 2015 Aug; 12(2):2417-24. PubMed ID: 25936357
[TBL] [Abstract][Full Text] [Related]
11. Quinomycin A targets Notch signaling pathway in pancreatic cancer stem cells.
Ponnurangam S; Dandawate PR; Dhar A; Tawfik OW; Parab RR; Mishra PD; Ranadive P; Sharma R; Mahajan G; Umar S; Weir SJ; Sugumar A; Jensen RA; Padhye SB; Balakrishnan A; Anant S; Subramaniam D
Oncotarget; 2016 Jan; 7(3):3217-32. PubMed ID: 26673007
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of NOTCH signaling pathway chemosensitizes HCC CD133
Hemati H; Kaur J; Sobti RC; Trehanpati N
Biochem Biophys Res Commun; 2020 May; 525(4):941-947. PubMed ID: 32173531
[TBL] [Abstract][Full Text] [Related]
13. Notch signaling plays a crucial role in cancer stem-like cells maintaining stemness and mediating chemotaxis in renal cell carcinoma.
Xiao W; Gao Z; Duan Y; Yuan W; Ke Y
J Exp Clin Cancer Res; 2017 Mar; 36(1):41. PubMed ID: 28279221
[TBL] [Abstract][Full Text] [Related]
14. Blocking NOTCH pathway can enhance the effect of EGFR inhibitor through targeting CD133+ endometrial cancer cells.
Shang C; Lang B; Meng LR
Cancer Biol Ther; 2018 Feb; 19(2):113-119. PubMed ID: 27791463
[TBL] [Abstract][Full Text] [Related]
15. Pretreatment with the γ-secretase inhibitor DAPT sensitizes drug-resistant ovarian cancer cells to cisplatin by downregulation of Notch signaling.
Wang M; Ma X; Wang J; Wang L; Wang Y
Int J Oncol; 2014 Apr; 44(4):1401-9. PubMed ID: 24535252
[TBL] [Abstract][Full Text] [Related]
16. Inhibiting Notch Activity in Breast Cancer Stem Cells by Glucose Functionalized Nanoparticles Carrying γ-secretase Inhibitors.
Mamaeva V; Niemi R; Beck M; Özliseli E; Desai D; Landor S; Gronroos T; Kronqvist P; Pettersen IK; McCormack E; Rosenholm JM; Linden M; Sahlgren C
Mol Ther; 2016 May; 24(5):926-36. PubMed ID: 26916284
[TBL] [Abstract][Full Text] [Related]
17. Cisplatin selects for stem-like cells in osteosarcoma by activating Notch signaling.
Yu L; Fan Z; Fang S; Yang J; Gao T; Simões BM; Eyre R; Guo W; Clarke RB
Oncotarget; 2016 May; 7(22):33055-68. PubMed ID: 27102300
[TBL] [Abstract][Full Text] [Related]
18. Notch Signaling in Breast Cancer: A Role in Drug Resistance.
BeLow M; Osipo C
Cells; 2020 Sep; 9(10):. PubMed ID: 33003540
[TBL] [Abstract][Full Text] [Related]
19. Coencapsulation of epirubicin and metformin in PEGylated liposomes inhibits the recurrence of murine sarcoma S180 existing CD133+ cancer stem-like cells.
Yang Q; Zhang T; Wang C; Jiao J; Li J; Deng Y
Eur J Pharm Biopharm; 2014 Nov; 88(3):737-45. PubMed ID: 25460146
[TBL] [Abstract][Full Text] [Related]
20. γ-secretase inhibitor-I enhances radiosensitivity of glioblastoma cell lines by depleting CD133+ tumor cells.
Lin J; Zhang XM; Yang JC; Ye YB; Luo SQ
Arch Med Res; 2010 Oct; 41(7):519-29. PubMed ID: 21167391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
